- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06840886
Une étude de PhST001 dans des tumeurs solides avancées
Une étude ouverte, phase 1a / 1b, étude d'escalade de dose et de dose étudiant sur la sécurité, la pharmacocinétique, la pharmacodynamique et l'activité antitumorale de PHST001 chez les patients adultes atteints de tumeurs solides en rechute et / ou réfractaires avancées
This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with anticancer therapies (Phase 1b) in adult participants with advanced relapsed and/or refractory solid tumors (including but not limited to CNS tumors in Phase 1a only). Phase 1b will include the following cohorts 1) tumor-specific cohorts for participants with advanced relapsed and/or refractory ovarian cancer, endometrial cancer, and cholangiocarcinoma, 2) a randomized cohort for participants with ovarian cancer who will receive PHST001 in combination with mirvetuximab soravtansine, 3) a cohort for participants with advanced/metastatic breast cancer who will receive PHST001 in combination with trastuzumab deruxtecan and 4) a cohort of patients who consent to additional biomarker studies.
The study's primary objectives are to evaluate the safety and tolerability of PHST001 and determine the RP2D (Recommended Phase 2 dose) of PHST001 as monotherapy and in combination with anticancer therapies, as well as to assess the anti-tumor activity of PHST001 in combination with anticancer therapies in Phase 1b.
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Estimé)
Phase
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: Raphaël Rousseau, Chief Medical Officer, PhD, MD
- Numéro de téléphone: 650-260-8443
- E-mail: medical@pheast.com
Lieux d'étude
-
-
California
-
Beverly Hills, California, États-Unis, 90212
- Recrutement
- Precision NextGen Oncology & Research Center
-
Contact:
- Jing Liu
- Numéro de téléphone: 424-777-0708
- E-mail: JingL@nextgenonc.com, research@nextgenonc.com
-
Chercheur principal:
- Kamlesh Kumar Sankhala, MD
-
Los Angeles, California, États-Unis, 90033
- Recrutement
- USC Norris Comprehensive Cancer Center
-
Contact:
- Lorraine Martinez
- E-mail: Lorraine.Martinez@med.usc.edu
-
Contact:
- Stephanie Kim
- E-mail: Stephanie.Kim2@med.usc.edu
-
Palo Alto, California, États-Unis, 94304
- Recrutement
- Stanford University School of Medicine
-
Contact:
- Kayla McDaniel
- Numéro de téléphone: 650-498-7293
- E-mail: mcda59@stanford.edu
-
Chercheur principal:
- Oliver Dorigo, MD, PhD
-
-
Colorado
-
Denver, Colorado, États-Unis, 80218
- Recrutement
- Sarah Cannon Research Institute (SCRI) Oncology Partners - Denver Health One
-
Contact:
- Sarah Cannon Research Institute at HCA HealthONE
- Numéro de téléphone: 720-754-2610
- E-mail: CANN.DDUDenverGeneral@SarahCannon.com
-
-
Connecticut
-
New Haven, Connecticut, États-Unis, 06520
- Recrutement
- Yale Cancer Center
-
Chercheur principal:
- Michael Cecchini, MD
-
Contact:
- Priscilla Stéve
- Numéro de téléphone: 203-464-5564
- E-mail: Priscilla.steve@yale.edu
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60637
- Recrutement
- University of Chicago Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02215
- Recrutement
- Dana Farber Cancer Institute
-
Chercheur principal:
- Michael Dennis, MD
-
Contact:
- DFCI CCTI Referrals
- E-mail: dfcicctiexternalreferral@dfci.harvard.edu
-
-
Michigan
-
Ann Arbor, Michigan, États-Unis, 48109
- Recrutement
- University of Michigan Rogel Cancer Center
-
Chercheur principal:
- Ulka Vaishampayan, MD
-
Contact:
- University of Michigan Health Cancer AnswerLine
- Numéro de téléphone: 1-800-865-1125
- E-mail: canceranswerline@med.umich.edu
-
Grand Rapids, Michigan, États-Unis, 49546
- Recrutement
- START Center for Cancer Research - Midwest
-
Chercheur principal:
- Sreenivasa Chandana, MD, PhD
-
Contact:
- START HOPE Team
- E-mail: hopeteam@startresearch.com
-
-
New York
-
Lake Success, New York, États-Unis, 11042
- Recrutement
- START Center for Cancer Research - Long Island New York
-
Chercheur principal:
- Geraldine O'Sullivan Coyne, MD
-
Contact:
- Sadia Morium
- Numéro de téléphone: 363-207-5166
- E-mail: sadia.morium@startresearch.com
-
New York, New York, États-Unis, 10029
- Recrutement
- Mount Sinai
-
Chercheur principal:
- Thomas Marron, MD, PhD
-
Contact:
- Jordan Cuevas
- Numéro de téléphone: 212-824-7945
- E-mail: jordan.cuevas@mssm.edu
-
-
North Carolina
-
Durham, North Carolina, États-Unis, 27710
- Recrutement
- Duke Cancer Institute
-
Contact:
- Phase 1 and Immunotherapy Team
- Numéro de téléphone: 919-684-6342
- E-mail: Phase1andImmunotherapyreferrals@duke.edu
-
Chercheur principal:
- Niharika Mettu, MD, PhD
-
-
Tennessee
-
Nashville, Tennessee, États-Unis, 37203
- Recrutement
- Vanderbilt-Ingram Cancer Center
-
Contact:
- Clinical Trials Office (CTO)
- Numéro de téléphone: 1-800-811-8480
- E-mail: cip@vumc.org
-
Chercheur principal:
- Elizabeth Davis, MD, PhD
-
Nashville, Tennessee, États-Unis, 37203
- Recrutement
- Sarah Cannon Research Institute (SCRI) Oncology Partners
-
Chercheur principal:
- Deepak Bhamidipati, MD
-
Contact:
- SCRI Oncology Partners - Nashville
- Numéro de téléphone: 1-877-MY-1-SCRI (691-7274)
- E-mail: ASKSARAH@scresearch.net
-
-
Texas
-
Fort Worth, Texas, États-Unis, 76104
- Recrutement
- START Center for Cancer Research - Texas
-
Contact:
- START HOPE Team
- E-mail: hopeteam@startresearch.com
-
Chercheur principal:
- Henry Xiong, MD, PhD
-
Houston, Texas, États-Unis, 77030
- Recrutement
- MD Anderson Cancer Center
-
Contact:
- MD Anderson Cancer Center
- Numéro de téléphone: 713-563-1930
- E-mail: ICTNPCS@mdanderson.org
-
Chercheur principal:
- Stéphane Champiat, MD, PhD
-
Irving, Texas, États-Unis, 75039
- Recrutement
- NEXT Oncology - Dallas
-
Chercheur principal:
- Michael Song, MD, PhD, PharmD
-
Contact:
- NEXT Referrals-Dallas
- Numéro de téléphone: fax: 210-568-4577
- E-mail: nxt_txreferrals@nextoncology.com
-
San Antonio, Texas, États-Unis, 78229
- Recrutement
- University of Texas (UT) Health
-
Chercheur principal:
- Daruka Mahadevan, MD, PhD
-
Contact:
- Mays Cancer Center Research Team
- E-mail: mccresearch@uthscsa.edu
-
San Antonio, Texas, États-Unis, 78229
- Recrutement
- START Center for Cancer Research - San Antonio
-
Chercheur principal:
- Kyriakos Papadopoulos, MD
-
Contact:
- START HOPE Team
- Numéro de téléphone: 210-593-5250
- E-mail: hopeteam@startresearch.com
-
-
Virginia
-
Fairfax, Virginia, États-Unis, 22031
- Recrutement
- NEXT Oncology - Virginia
-
Contact:
- Carrie Friedman
- E-mail: adelgado@nextoncology.com
-
Contact:
- Allison Delgado
- E-mail: carrie.friedman@usoncology.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Key Inclusion Criteria:
- Histologically or cytologically confirmed advanced solid tumor which has relapsed from or been refractory to all locally available standard therapies.
- Adequate organ function per laboratory testing
- Pregnancy prevention requirements
- Measurable disease per RECIST v1.1 (or RANO) as assessed by the local site Investigator/radiology
- Performance status of 0 or 1 on Eastern Cooperative Oncology Group (ECOG) scale
Key Exclusion Criteria:
- Diagnosis of immunodeficiency
- History of a previous additional malignancy, unless potentially curative treatment has been completed, with no evidence of malignancy for 2 years. Participants with basal cell carcinoma of the skin, Stage I melanoma, melanoma in situ, squamous cell carcinoma of the skin, early-stage prostate cancer, low grade neoplasms, or carcinoma in situ, excluding carcinoma in situ of the bladder, who have undergone potentially curative therapy are not excluded and can be enrolled regardless of disease-free period following completion of potentially curative therapy. Participants with early-stage breast cancer who have undergone curative intent treatment and with no disease recurrence for 2 years after treatment are not excluded.
- Active known CNS metastases and/or carcinomatous meningitis from a systemic (non-CNS) primary malignancy. Participants with previously treated CNS metastases are eligible, provided they are radiologically and clinically stable (i.e., no evidence of progression for at least 2 weeks by repeat imaging performed during screening) and are not requiring systemic corticosteroids above the physiologic replacement for at least 7 days prior to the first dose of study treatment.
- Received prior systemic anticancer therapy including investigational agents within 21 days or, if shorter, within 5 half-lives prior to the first dose of study treatment. Participants must have recovered from all AEs due to previous therapies to Grade ≤1 or baseline. Participants with Grade ≤2 neuropathy may be eligible. Participants with endocrine-related AEs Grade ≤2 requiring treatment or hormone replacement may be eligible.
- Prior autologous or allogeneic hematopoietic stem cell transplant or solid organ transplant.
- Received previous treatment with another agent targeting CD24.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation séquentielle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: PHST001 Monotherapy
Participants will receive PHST001 monotherapy administered once every 3 weeks (Q3W). In Phase 1a, PHST001 will be evaluated in sequential dose-escalation cohorts at planned dose levels of 0.1, 0.3, 1.0, 2.0, 4.0, 6.0, 9.0, 18.0, and 36.0 mg/kg. Dose levels may be modified or additional dose levels evaluated based on emerging safety, pharmacokinetic, pharmacodynamic, and antitumor activity data. Participants in the Phase 1b biomarker cohort may also receive PHST001 monotherapy. |
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals. |
|
Expérimental: PHST001 + Paclitaxel
Participants will receive PHST001 in combination with paclitaxel. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in tumor-specific expansion cohorts, including participants with ovarian carcinoma, endometrial carcinoma, or cholangiocarcinoma, and/or in the biomarker cohort. |
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals. Paclitaxel used as per standard of care.
Autres noms:
|
|
Expérimental: PHST001 + Topotecan
Participants will receive PHST001 in combination with topotecan. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in the ovarian carcinoma expansion cohort and/or biomarker cohort. |
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals. Topotecan used as per standard of care.
Autres noms:
|
|
Expérimental: PHST001 + Doxorubicin
Participants will receive PHST001 in combination with doxorubicin. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in ovarian carcinoma or endometrial carcinoma expansion cohorts and/or the biomarker cohort. |
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals. Doxorubicin used as per standard of care.
Autres noms:
|
|
Expérimental: PHST001 + FOLFIRI
Participants will receive PHST001 in combination with FOLFIRI (5-fluorouracil, folinic acid, and irinotecan). The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in the cholangiocarcinoma expansion cohort and/or biomarker cohort. |
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals. FOLFIRI used as per standard of care.
Autres noms:
|
|
Expérimental: PHST001 + FOLFOX
Participants will receive PHST001 in combination with FOLFOX (5-fluorouracil, folinic acid, and oxaliplatin). The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in the cholangiocarcinoma expansion cohort and/or biomarker cohort. |
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals. FOLFOX used as per standard of care.
Autres noms:
|
|
Expérimental: PHST001 + Gemcitabine
Participants will receive PHST001 in combination with gemcitabine. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in ovarian carcinoma or cholangiocarcinoma expansion cohorts and/or the biomarker cohort. |
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals. Gemcitabine used as per standard of care.
Autres noms:
|
|
Expérimental: PHST001 + Mirvetuximab Soravtansine
Participants will receive PHST001 in combination with mirvetuximab soravtansine. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in the ovarian carcinoma expansion cohort and/or in the biomarker cohort. Half of the participants in the randomized ovarian carcinoma cohort may be randomly assigned to receive PHST001 in combination with mirvetuximab soravtansine. |
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals. Mirvetuximab soravtansine used as per standard of care.
Autres noms:
|
|
Expérimental: PHST001 + Trastuzumab Deruxtecan
Participants will receive PHST001 in combination with trastuzumab deruxtecan. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in participants with advanced or metastatic breast cancer and/or in the biomarker cohort. |
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals. Trastuzumab deruxtecan used as per standard of care.
Autres noms:
|
|
Comparateur actif: Mirvetuximab Soravtansine Monotherapy
Participants with ovarian carcinoma enrolled in the randomized Phase 1b expansion cohort will be randomized 1:1 to receive mirvetuximab soravtansine monotherapy or mirvetuximab soravtansine in combination with PHST001. Participants assigned to this arm will receive mirvetuximab soravtansine monotherapy. |
Mirvetuximab soravtansine used as per standard of care.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Frequency of Dose-Limiting Toxicities (DLTs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Délai: From first dose of PHST001 through 21 days after the first dose of PHST001
|
Based on toxicities observed |
From first dose of PHST001 through 21 days after the first dose of PHST001
|
|
Frequency of Serious Adverse Events (SAEs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Délai: From signed consent up to 90 days after the last dose of PHST001
|
Based on toxicities observed |
From signed consent up to 90 days after the last dose of PHST001
|
|
Frequency of Treatment Emergent Adverse Events (TEAEs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Délai: From first dose up to 90 days after the last dose of PHST001
|
Based on toxicities observed |
From first dose up to 90 days after the last dose of PHST001
|
|
Frequency of Treatment Related Adverse Events (TRAEs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Délai: From first dose up to 90 days after the last dose of PHST001
|
Based on toxicities observed |
From first dose up to 90 days after the last dose of PHST001
|
|
Frequency of Adverse Events of Special Interest (AESIs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Délai: From first dose up to 90 days after the last dose of PHST001
|
Based on toxicities observed |
From first dose up to 90 days after the last dose of PHST001
|
|
Frequency of AEs Leading to Dose Interruption or Treatment Discontinuation and AEs Leading to Death to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Délai: From first dose up to 90 days after the last dose of PHST001
|
Based on toxicities observed |
From first dose up to 90 days after the last dose of PHST001
|
|
Overall Response Rate (ORR) based on RECIST v1.1 to assess the preliminary antitumor activity of PHST001 in combination with anticancer therapy (Phase 1b non-randomized cohorts only)
Délai: From screening and during treatment up to 2 years
|
Defined as the proportion of subjects with confirmed complete response (CR) or partial response (PR); a confirmed response is a response that persists on repeat-imaging ≥ 4 weeks after initial documentation of response. |
From screening and during treatment up to 2 years
|
|
Progression-Free Survival (PFS) based on RECIST v1.1 to assess the preliminary antitumor activity of PHST001 in combination with anticancer therapy (Phase 1b randomized cohort only)
Délai: From screening and during treatment up to 2 years
|
Defined as the time from first dose of PHST001 to first documentation of radiographic disease progression or death, whichever occurs first. |
From screening and during treatment up to 2 years
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Overall Response Rate (ORR) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b - randomized cohort only)
Délai: From screening and during treatment up to 2 years
|
Defined as the proportion of subjects with confirmed complete response (CR) or partial response (PR); a confirmed response is a response that persists on repeat-imaging ≥ 4 weeks after initial documentation of response. |
From screening and during treatment up to 2 years
|
|
Duration of Response (DOR) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b)
Délai: From screening and during treatment up to 2 years
|
Defined as time from date of first objective response (either CR or PR) to first documentation of radiographic disease progression. |
From screening and during treatment up to 2 years
|
|
Best Overall Response (BOR) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b)
Délai: From screening and during treatment up to 2 years
|
Defined as the best response recorded for a participant across all time-point assessments from the start of treatment until disease progression or end of treatment. |
From screening and during treatment up to 2 years
|
|
Progression-Free Survival (PFS) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b - non-randomized cohorts only) .
Délai: From screening and during treatment up to 2 years
|
Defined as the time from first dose of PHST001 to first documentation of radiographic disease progression or death, whichever occurs first. |
From screening and during treatment up to 2 years
|
|
Overall Survival (OS) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b).
Délai: From screening and during treatment up to 2 years
|
Defined as the time from first dose of PHST001 to the date of death. |
From screening and during treatment up to 2 years
|
|
Maximum Observed Concentration (Cmax) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b).
Délai: From treatment until 90 days after last dose of PHST001
|
Defined as the maximum blood concentration of a dose of PHST001 |
From treatment until 90 days after last dose of PHST001
|
|
Time to Maximum Concentration (tmax) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Délai: From treatment until 90 days after last dose of PHST001
|
Defined as the time required for a dose of PHST001 to reach its maximum blood concentration (Cmax) after administration. |
From treatment until 90 days after last dose of PHST001
|
|
Concentration at the End of a Dosing Interval (Ctrough) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Délai: From treatment until 90 days after last dose of PHST001
|
Defined as the blood concentration of a dose of PHST001 at the end of the dosing interval (just prior to next drug administration). |
From treatment until 90 days after last dose of PHST001
|
|
Area Under the Concentration-time Curve (AUC) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Délai: From treatment until 90 days after last dose of PHST001
|
Defined as the total PHST001 exposure over time, calculated as the integral of the plasma concentration-time profile. |
From treatment until 90 days after last dose of PHST001
|
|
Volume of Distribution at Steady-state (Vss) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Délai: From treatment until 90 days after last dose of PHST001
|
Defined as how widely PHST001 spreads throughout the body once things have stabilized after a dose has been administered. |
From treatment until 90 days after last dose of PHST001
|
|
Clearance (CL) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Délai: From treatment until 90 days after last dose of PHST001
|
Defined as the rate at which the body "cleans out" a dose of PHST001 from the bloodstream. |
From treatment until 90 days after last dose of PHST001
|
|
Terminal Elimination Half-life (t½) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Délai: From treatment until 90 days after last dose of PHST001
|
Defined as the time it takes for the amount of PHST001 in the body to drop by half during the final phase of elimination. |
From treatment until 90 days after last dose of PHST001
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies urogénitales
- Maladies génitales
- Maladies du système endocrinien
- Maladies du système nerveux
- Tumeurs urogénitales
- Tumeurs par site
- Tumeurs
- Maladies urogénitales féminines
- Maladies urogénitales féminines et complications de la grossesse
- Tumeurs par type histologique
- Maladies utérines
- Maladies génitales, femme
- Tumeurs des glandes endocrines
- Tumeurs, glandulaires et épithéliales
- Adénocarcinome
- Maladies ovariennes
- Maladies annexielles
- Tumeurs génitales, femme
- Troubles gonadiques
- Maladies de la peau
- Maladies du sein
- Carcinome
- Tumeurs du système nerveux
- Tumeurs utérines
- Sarcome
- Tumeurs, tissus conjonctifs et mous
- Tumeurs, complexes et mixtes
- Maladies des trompes de Fallope
- Maladies de la peau et du tissu conjonctif
- Tumeurs ovariennes
- Tumeurs mammaires
- Cholangiocarcinome
- Tumeurs de l'endomètre
- Carcinosarcome
- Tumeurs du système nerveux central
- Tumeurs des trompes de Fallope
- Produits chimiques organiques
- Composés hétérocycliques, 1 anneau
- Composés hétérocycliques
- Composés hétérocycliques, 2 anneaux
- Composés hétérocycliques, anneau fusionné
- Hydrocarbures
- Cycloparaffines
- Hydrocarbures, alicyclique
- Hydrocarbures, cyclique
- Terpènes
- Glucides
- Camptothécine
- Alcaloïdes
- Hydrocarbures aromatiques polycycliques
- Hydrocarbures, aromatique
- Composés polycycliques
- Glycosides
- Enzymes et coenzymes
- Taxes
- Cyclodécanes
- Diterpènes
- Désoxycytidine
- Cytidine
- Nucléosides pyrimidine
- Pyrimidines
- Formyltétrahydrofolate
- Tétrahydrofolat
- Acide folique
- Pterines
- Ptéridines
- Uracile
- Pyrimidinones
- Anthracyclines
- Naphtacènes
- Aminoglycosides
- Coenzymes
- Daunorubicine
- Gemcitabine
- Fluorouracile
- Leucovorine
- Doxorubicine
- Paclitaxel
- Topotécan
- mirvetuximab soravtansine
- trastuzumab deruxecan
- Protocole Folfox
- Protocole IFL
Autres numéros d'identification d'étude
- PHST001-101
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .